Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. - Wikidata - awgldk - TriplyDB

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

http://www.wikidata.org/entity/Q34973845

about

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects Antituberculosis therapy for 2012 and beyond Nitroimidazoles for the treatment of TB: past, present and future Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis Tuberculosis therapy for 2016 and beyond.Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis Drug-resistant tuberculosis: emerging treatment options.Current development and future prospects in chemotherapy of tuberculosis A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Managing TB in the 21st century: existing and novel drug therapies.Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.Mycobacterium tuberculosis: drug resistance and future perspectives.Recent advances in antituberculous drug development and novel drug targets.The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.New treatment options for multidrug-resistant tuberculosis.Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.Targeting the mycobacterial envelope for tuberculosis drug development.PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.The early bactericidal activity of antituberculosis drugs.The anti-tuberculosis agents under development and the challenges ahead.Maximizing bactericidal activity with combinations of bioreduced drugs.

P2860

Q24641829-6959BDA3-163A-445B-8945-AA944503141B Q26829101-340BB721-34CC-4E39-9ECB-D924E8C72403 Q26849554-86A00C60-2DA9-4CD1-AC5C-C066A70067AD Q28542435-E9EBFD74-731B-44B1-A8EA-520CFC504AAE Q30248788-7DF28DA7-F4C9-4B3C-8D55-4196421FD05C Q33589762-29D2F233-C0EA-4F9C-B396-832A066E3825 Q33768799-8325B03D-3326-4FAA-993A-562A33999250 Q34045233-1D914299-472B-47F6-9B3B-9D6E4BABA86F Q34483632-F96CCDB2-DC54-4B37-B39A-8C350B6FBA29 Q34737143-B1C61003-F52F-4952-9B32-E0652704BE8E Q34922056-9DD7D35A-EE5B-496D-AC69-46E06697B080 Q35171238-8E8138BD-A7F2-461F-9F41-1CA8F51EF745 Q35598474-F10D3B5F-0CB1-429D-80B1-B15F8E25058E Q35683967-417D90E1-7D75-4070-B68A-D8D414BF5DDC Q35705874-2B506675-B43F-40ED-AFF7-E48988A977DE Q35745991-2BF64E7B-C02B-43B6-B79F-853F24D3D16C Q36018624-3BD5C06B-96B2-4BF3-A427-281F1C65C641 Q36171524-5AC18D44-DAE2-4C4A-8E70-20D93F856F69 Q36236341-7368E472-814F-44B5-AA4F-F99D9E9C9FA9 Q36538719-32F3F3E2-8E22-4045-8FD9-5479AD623E59 Q36932905-7DB49514-46AE-4F7C-8530-9C52F2D78FED Q36932992-4C7BEEC9-0D93-40F1-A441-A983AB0BC887 Q37036499-68225838-A3D4-4886-B111-4E32176214A2 Q37107614-5C45D88D-9CC2-467A-B34B-10AE26C3C464 Q37144892-6920E656-0E5A-477C-A8D4-ABCE1A85444F Q37144919-9DF537C4-0927-453A-9EE7-BB5F20ABF08A Q37333140-409EF9FF-D41D-4E2C-8E0F-908DE3F830BF Q37346929-835112EA-AD6A-4658-BFA3-C85C05DACE32 Q37362655-EA9903F7-2782-426E-BABE-F6E1A952ED7C Q37392767-D80F87A7-DEA7-4AC1-AD25-4DD745E960D3 Q37506524-88C34E8B-5B2B-4FEE-8084-FB0D585E6FC9 Q37754884-B9276FEC-F243-433E-9B71-738301562777 Q37855837-69FA0A80-6451-46C3-920B-D8F0C412F0A6 Q38024041-963FB442-B04F-4F27-80BB-94293F9278F8 Q38044744-96283C8A-A828-4CD9-B99C-1199ACD3A2A1 Q38056149-2167F9AD-4266-4DD9-9049-4D7A40F76935 Q38107959-959F198C-EF37-4F21-91C4-BCDD2EDB7AC0 Q38176039-275E95AC-6233-4C50-91F9-FEA2DEA94A3D Q38617197-26278A72-B503-4D88-AC19-3D2B4C706D85 Q39769351-6FC5E3A5-5DF0-4068-B420-D10816E3DD5C

P2860

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

http://www.wikidata.org/entity/Q34973845

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Combination chemotherapy with ...... murine model of tuberculosis.

@ast

Combination chemotherapy with ...... murine model of tuberculosis.

@en

Combination chemotherapy with ...... murine model of tuberculosis.

@nl

type

label

Combination chemotherapy with ...... murine model of tuberculosis.

@ast

Combination chemotherapy with ...... murine model of tuberculosis.

@en

Combination chemotherapy with ...... murine model of tuberculosis.

@nl

prefLabel

Combination chemotherapy with ...... murine model of tuberculosis.

@ast

Combination chemotherapy with ...... murine model of tuberculosis.

@en

Combination chemotherapy with ...... murine model of tuberculosis.

@nl

P1433

Q34973845-C3F5115F-EC4C-4D95-8B56-EBED89958B3E

P1476

Q34973845-B8491078-0344-46E4-8B99-0C3420603346

P2093

Q34973845-076201B4-3DB1-41D4-81BD-E1BCA32EB7F4

Q34973845-1C151572-EBC6-4620-8379-AAC4C5999C66

Q34973845-4AFF558C-F13C-493B-9491-70AC0C39024C

Q34973845-5A4F13DA-B408-4967-8E0D-85841C80FEB5

Q34973845-AA638568-A7B3-4E78-87E5-D0590C0DE956

Q34973845-E31F9A0B-8CB5-4910-8302-F33A9CB4A71C

Q34973845-EA052838-3350-408C-895A-48DB796E909B

Q34973845-ED0B593B-AB3D-4AA8-B97A-30BB415B09B4

P2860

Q34973845-0288AB22-BF16-4BC3-A0F4-8B54C7F8AAF7

Q34973845-133239D2-1518-44B9-8DC9-00786B618A7D

Q34973845-1D08B753-BD4B-4AC7-AE56-67621CAFD20E

Q34973845-356E096A-9C33-462B-B8BE-05DD9FEE5938

Q34973845-373F7137-7C01-4046-86A9-B658EA5C2B9A

Q34973845-67DFBFB4-DCD3-4702-B796-87D47C0A2BDC

Q34973845-83198E0A-2BD0-485B-97D4-CD6C420210B1

Q34973845-88C73AF3-0085-4496-AFFD-0DD794557358

Q34973845-98397E56-9AD3-4327-A735-202BFBA6FB27

Q34973845-A5DB996A-7024-4627-A911-485904617333

P304

Q34973845-BF8D2F28-412E-4E6A-B7ED-46DBD6B7AFC5

P31

Q34973845-D43B2558-E568-41F3-8637-6DC0440A3F03

P356

Q34973845-555C003B-525E-4125-B712-C3A87DB35789

P407

Q34973845-E7B9CB12-5A8D-473C-AF75-AF29BBF52A1F

P433

Q34973845-1467EBC7-00AA-45E4-848B-045E9C7D27DA

P478

Q34973845-61EFC0EA-8673-44F7-93E9-AB18BFA97E54

P577

Q34973845-7647C4C3-9D22-40FC-94FF-505F7C3EDC92

P5875

Q34973845-BA4FDC61-E847-4109-99EC-8BF02FCCC794

P698

Q34973845-83AC84A4-3CB8-4BC4-8BDC-BD4FFEBBBFC6

P921

Q34973845-A332229C-9766-4CF4-93FC-D63BC6349484

Q34973845-FA41D3CF-88D1-4220-9395-2D4BBAFC2B51

P932

Q34973845-AD4C9641-5032-4FE1-A9EC-A185956AF000

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Combination chemotherapy with ...... murine model of tuberculosis.

@en

P2093

Charles A Peloquin

http://www.w3.org/2001/XMLSchema#string

Deepak Almeida

http://www.w3.org/2001/XMLSchema#string

Eric Nuermberger

http://www.w3.org/2001/XMLSchema#string

Ian Rosenthal

http://www.w3.org/2001/XMLSchema#string

Jacques H Grosset

http://www.w3.org/2001/XMLSchema#string

Kathy N Williams

http://www.w3.org/2001/XMLSchema#string

Sandeep Tyagi

http://www.w3.org/2001/XMLSchema#string

William R Bishai

http://www.w3.org/2001/XMLSchema#string

P2860

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.

Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis.

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps.

Basic mechanisms of chemotherapy.

P304

2621-2625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00451-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6915199

http://www.w3.org/2001/XMLSchema#string

P698

16870750

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

1538692

http://www.w3.org/2001/XMLSchema#string